The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms.
ID
Source
Brief title
Condition
- Heart failures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The composite primary endpoint for this trial is the time to first event of
adjudicated CV death or adjudicated HHF in patients with HFpEF.
Secondary outcome
The key secondary endpoints which are part of the testing strategy, are the
following:
- Occurrence of adjudicated HHF (first and recurrent)
- eGFR (CKD-EPI)cr slope of change from baseline
Other secondary endpoints are:
- Time to first occurrence of chronic dialysis or renal transplant or sustained
reduction of *40% eGFR (CKD-EPI)cr or
a sustained eGFR (CKD-EPI)cr <15 mL/min/1.73 m2 for patients with baseline eGFR
*30 mL/min/1.73 m2
b sustained eGFR (CKD-EPI)cr <10 mL/min/1.73 m2 for patients with baseline eGFR
<30 mL/min/1.73 m2
*An eGFR (CDK-EPI)cr reduction is considered sustained, if it is determined by
two or more consecutive post-baseline central laboratory
measurements separated by at least 30 days (first to last of the consecutive
eGFR values). Chronic dialysis is defined as dialysis with a frequency of twice
per week or more often for at least 90 days.
* Time to first adjudicated HHF
* Time to adjudicated CV death
* Time to all-cause mortality
* Time to onset of diabetes mellitus (DM) in patients with pre-DM
* Change from baseline in clinical summary score (HF symptoms and physical
limitations domains) of the KCCQ at week 52
* Occurrence of all-cause hospitalisation (first and recurrent)
Background summary
Chronic heart failure (HF) is a progressive syndrome characterised by the
inability of the heart to provide adequate blood supply to meet the metabolic
demand of different tissues or do it at the expense of elevated left ventricle
filling pressure. HF is a prevalent disease affecting an estimated 26 million
people worldwide. In the United States alone the prevalence is 5.7 million, and
there are 670,000 new cases per year. HF is associated with premature mortality
and frequent hospitalisation. Approximately 50% of patients who develop HF die
within 5 years after diagnosis. Annually, more than 1 million patients are
hospitalised with a primary diagnosis of HF. Two types of HF have been defined
mainly based on the LV ejection fraction (EF) and also other structural changes
in heart muscle. They consist of heart failure with reduced EF (HFrEF) *40% and
heart failure with preserved EF (HFpEF) >40%.
About 25 to 45% of patients with HF have concomitant type 2 diabetes mellitus
(T2DM), and nearly 15-25% have borderline DM (pre-diabetes), indicating a
potential link between the HF syndromes and glucometabolic disturbances.
Empagliflozin is an orally available inhibitor of the renal dependent glucose
co-transporter 2 (SGLT-2) indicated for, reduction of blood glucose in patients
with T2DM by promoting urinary glucose excretion. It also reduces blood
pressure, arterial stiffness and measures of the myocardial workload, likely
through various mechanisms, as well as improving other CV risk factors (uric
acid, visceral fat mass, albuminuria)
Study objective
The objective of this event-driven trial is to demonstrate superiority of
empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and
preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms.
Study design
This randomised, double-blind, multi-national, parallel group trial compares
empagliflozin 10 mg once daily to placebo as add-on to standard of care
treatment in patients with HFpEF.
Intervention
* 4-21 days screening period
* Approximately 20-38 months double-blind treatment until the required number
of adjudicated primary events is reached with empagliflozin or placebo
* Follow-up visit 30 days after end of treatment
The trial will continue until required number of adjudicated primary endpoint
events have occurred to be able to comply with the objective of the trial.
Subjects will be treated with empagliflozin or placebo tablets once daily
Study burden and risks
Possible side effects:
- Hypoglycaemia
- Major hypoglycaemia (events requiring assistance)
- Urinary tract infection
- Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection
- Increased urination
- Volume depletion
- Blood creatinine increased and glomerular filtration rate decreased
Possible side effects are described in the Investigators Brochure.
Binger Strasse 173
Ingelheim am Rhein 55216
DE
Binger Strasse 173
Ingelheim am Rhein 55216
DE
Listed location countries
Age
Inclusion criteria
* Patients with chronic HF diagnosed for at least 3 months before Visit 1 and currently in HF NYHA class II-IV
* Chronic HF with preserved EF defined as LVEF > 40 % per local reading (obtained by echocardiography, radionuclide ventriculography, invasive angiography, MRI or CT), and no prior measurement of LVEF * 40% under stable conditions. A historical LVEF may be used if it was measured within 6 months prior to visit 1, and more than 90 days after any myocardial infarction (as defined in exclusion criterion No.1) or the LVEF may be measured after study consent has been obtained. The LVEF must be documented in an official report prior to randomization.
* Elevated NT-proBNP > 300 pg/ml for patients without AF, OR > 900 pg/ml for patients with AF, analysed at the Central laboratory at Visit 1
* Patients must have at least one of the following evidence of HF:
- Structural heart disease (left atrial enlargement and/or left
ventricular hypertrophy) documented by echocardiogram at Visit 1, OR
- Documented hospitalisation for HF (HHF) within 12 months prior to Visit 1
* Oral diuretics, if prescribed to patient according to local guideline and discretion of the Investigator, should be stable for at least 1 week prior to Visit 2 (Randomisation)
* eGFR (CKD-EPI)cr * 20 mL/min/1.73m2 at Visit 1
Exclusion criteria
* Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischaemia or newly developed ischaemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days prior to Visit 1
* Heart transplant recipient or listed for heart transplant
* Implantation of cardioverter defibrillator (ICD) within 3 months prior to Visit 1
* Implanted cardiac resynchronisation therapy (CRT)
* Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction
* Any severe (obstructive or regurgitant) valvular heart disease expected to lead to surgery during the trial in the Investigator*s opinion
* Acute decompensated HF (exacerbation of chronic HF) requiring intravenous (i.v.) diuretics, i.v. inotropes or i.v. vasodilators, or left ventricular assist device within 1 week from discharge to Visit 1, and during screening period until Visit 2 (Randomisation)
* Atrial fibrillation or atrial flutter with a resting heart rate > 110 bpm documented by ECG at Screening
* Systolic blood pressure (SBP) * 180 mmHg at Visit 2. If SBP >150 mmHg and <180 mmHg at Visit 2, the patient should be receiving at least 3 antihypertensive drugs
* Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| EudraCT | EUCTR2016-002278-11-NL |
| CCMO | NL59667.056.17 |